iBio enters $100M at-the-market equity agreement with Jefferies, terminates prior ATM

iBio, Inc.

Entered Open Market Sale Agreement (ATM) with Jefferies LLC for up to $100M of common stock.
Jefferies will receive up to 3.0% commission on gross proceeds from sales.
Terminated prior ATM agreement with Chardan Capital Markets and Craig-Hallum that allowed up to $7.35M.
Sales under new ATM to be made via Nasdaq or in privately negotiated transactions, subject to conditions.
Shelf registration statement filed Feb 27, 2026; no assurance of effectiveness.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

iBio, Inc. terminated At Market Issuance Sales Agreement with Chardan Capital Markets, LLC and Craig-Hallum Capital Group LLC valued at aggregate offering price of up to $7,350,000 (effective 2026-02-23).

Action: termination
Agreement: atm program
Counterparty: Chardan Capital Markets, LLC and Craig-Hallum Capital Group LLC
Value: aggregate offering price of up to $7,350,000
Effective: 2026-02-23

Exact text from the filing

On February 23, 2026, the Company provided notice terminating the At Market Issuance Sales Agreement (the “Prior ATM Agreement”), dated July 3, 2024, between the Company and Chardan Capital Markets, LLC and Craig-Hallum Capital Group LLC.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

iBio, Inc. entered into Open Market Sale Agreement SM with Jefferies LLC valued at up to $100,000,000 (effective 2026-02-27).

Action: entry
Agreement: atm program
Counterparty: Jefferies LLC
Value: up to $100,000,000
Effective: 2026-02-27

Exact text from the filing

On February 27, 2026, iBio, Inc., a Delaware corporation (the “Company”), entered into an Open Market Sale Agreement SM (the “ATM Agreement”) with Jefferies LLC (“Jefferies”) providing for the sale by the Company of its shares of common stock

View on SEC.gov

291 material agreements filed in the last 30 days. Browse all material agreements →

iBio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-021654

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.